Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].
Molecular Weight:
(145.72 kDa)
Purity:
99.64
CAS Number:
[1229575-09-0]
Target:
SARS-CoV
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted